← SynDRA
GSK-269962A
SynDRA canonical compound SYN0006456 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | ROCK1 | ROCK2 |
|---|
| Mechanism of action | rho associated kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- ROCK1 INHIBITOR
- ROCK2 INHIBITOR
- rho associated kinase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- MARK3
- PIM1
- SGK2
- RPS6KA5
- RPS6KA1
- LCK
- LRRK2
- SRPK1
- CDK2
- HIPK4
- HIPK2
- CDC42BPA
- PRKX
- GSK3B
- GSK3A
- SYK
- AURKA
- MKNK2
- PIM3
- AKT1
- AKT2
- MARK2
- FLT3
- PKN2
- AKT3
- AURKB
- PIM2
- PDGFRA
- PDGFRB
- PDK1
- PLK3
- PLK1
- PDPK1
- PHKG1
- PIK3CD
- PHKG2
- PKD1
- PI4KB
- PIK3CA
- PASK
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- KAPCA
- KS6A3
- TSSK1
- ST17A
- NSD2
- M4K5
- KSYK
- KS6B1
- KS6A5
- KPCZ
- KCC2B
- KPCI
- KPCG
- KPCD3
- KPCD2
- KPCD
- KGP2
- KGP1
- VGFR3
Cross-references
Synonyms
- GSK269962A
- GSK269962
- GSK-269962
- aminofurazanyl-azabenzimidazole 6n
- GSK 269962
- GSK269962B
- F89KMM7TE2
- RefChem:922534
- Aminofurazanyl-azabenzimidazole 6n
- MFCD09970310
- Kinome_3843
- C29H30N8O5
- UNII-F89KMM7TE2
- MLS006010261
- ROCK inhibitor GS269962A
- GTPL8037
- orb1304125
- SCHEMBL1838346
- ROCK inhibitor GSK269962A
- SCHEMBL29365470
- SCHEMBL29387396
- BDBM14047
- EX-A674
- YOVNFNXUCOWYSG-UHFFFAOYSA-N
- GLXC-90467
- IVA18608
- NSC756162
- AKOS024457925
- NSC-756162
- SDCCGGSK-0000025.P001
- NCGC00241982-01
- NCGC00241982-02
- NCGC00241982-03
- NCGC00241982-04
- NCGC00241982-09
- AC-35298
- AC-35503
- AS-56202
Look up GSK-269962A in the interactive SynDRA portal →